Globally, there is an investment boom in the field of cancer vaccines. Many companies are accelerating their research, development, and production efforts to gain a technological advantage and market opportunities.
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck's personalized cancer therapy business, with Personalis at the center of the bet.